Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 12/20 | 0.51 |
| ▸ | CDK12 | Q9NYV4 | 12/20 | 0.51 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 4/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.39 |
| ▸ | CDK2 | P24941 | 6/20 | 0.39 |
| ▸ | CDK7 | P50613 | 6/20 | 0.39 |
| ▸ | CCNH | P51946 | 6/20 | 0.39 |
| ▸ | MNAT1 | P51948 | 6/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30533943 | 1.00 | CCNK (0.51) | CCNKCDK12CDK13EGFRCCNA2 | |
| SCHEMBL25221073 | 0.92 | CDK12 (0.53) | CCNKCDK12CDK13EGFRCCNA2 | |
| SCHEMBL30533876 | 0.92 | CDK12 (0.53) | CCNKCDK12CDK13EGFRCCNA2 | |
| SCHEMBL30533789 | 0.89 | CDK12 (0.56) | CCNKCDK12CDK13EGFRCCNA2 | |
| SCHEMBL25268914 | 0.89 | CDK12 (0.56) | CCNKCDK12CDK13EGFRCCNA2 | |
| SCHEMBL25221756 | 0.88 | CCNK (0.39) | CCNKCDK12JAK3 | |
| SCHEMBL30533963 | 0.88 | CCNK (0.39) | CCNKCDK12JAK3 | |
| SCHEMBL25258833 | 0.85 | CCNK (0.36) | CCNKCDK12 | |
| SCHEMBL30464366 | 0.85 | CCNK (0.36) | CCNKCDK12 | |
| SCHEMBL25220788 | 0.81 | CCNK (0.47) | CCNKCDK12CDK13EGFRCCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | CCNK 17/4885CDK12 1/4885CDK13 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.